We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

81 hedge funds and large institutions have $136M invested in Palvella Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

736% more call options, than puts

Call options by funds: $903K | Put options by funds: $108K

50% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 14

8% more funds holding

Funds holding: 75 → 81 (+6)

0.02% more ownership

Funds ownership: 0.6% → 0.62% (+0.02%)

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

18% less capital invested

Capital invested by funds: $165M → $136M (-$29.2M)

Holders
81
Holders Change
+6
Holders Change %
+8%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
20
Reduced
22
Closed
14
Calls
$903K
Puts
$108K
Net Calls
+$795K
Net Calls Change
+$1.08M

Top Buyers

1
WP
Woodline Partners
California
+$9.86M
2
Marshall Wace
Marshall Wace
United Kingdom
+$7.94M
3
GPP
Great Point Partners
Connecticut
+$6.2M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$4.62M
5
Bank of America
Bank of America
North Carolina
+$1.66M

Top Sellers

1
Invesco
Invesco
Georgia
-$7.76M
2
Millennium Management
Millennium Management
New York
-$3.28M
3
Baird Financial Group
Baird Financial Group
Wisconsin
-$2.59M
4
EI
EAM Investors
California
-$1.49M
5
Morgan Stanley
Morgan Stanley
New York
-$1.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$20.1M – – –
ACM
2
Aquilo Capital Management
California
$12.1M – – –
WP
3
Woodline Partners
California
$9.31M +$9.86M +30,796 New
Marshall Wace
4
Marshall Wace
United Kingdom
$8.33M +$7.94M +24,804 +904%
Citadel Advisors
5
Citadel Advisors
Florida
$7.92M -$864K -2,697 -9%
GPP
6
Great Point Partners
Connecticut
$5.86M +$6.2M +19,375 New
Assenagon Asset Management
7
Assenagon Asset Management
Luxembourg
$5.58M +$4.62M +14,419 +358%
Morgan Stanley
8
Morgan Stanley
New York
$5.19M -$1.46M -4,558 -21%
BlackRock
9
BlackRock
New York
$4.98M +$161K +504 +3%
Millennium Management
10
Millennium Management
New York
$4.64M -$3.28M -10,241 -40%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$4.08M -$143K -448 -3%
CS
12
Candriam SCA
Luxembourg
$4.01M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$4.01M -$70.8K -221 -2%
PIM
14
Platinum Investment Management
Australia
$3.89M – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$3.88M -$559K -1,746 -12%
SCM
16
Soleus Capital Management
Connecticut
$2.6M -$210K -657 -7%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$2.45M -$180K -562 -6%
Citigroup
18
Citigroup
New York
$1.86M +$74.6K +233 +4%
Goldman Sachs
19
Goldman Sachs
New York
$1.82M -$63.7K -199 -3%
Bank of America
20
Bank of America
North Carolina
$1.61M +$1.66M +5,197 +3,660%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$1.5M -$271K -845 -15%
CCB
22
Cutter & Co Brokerage
Missouri
$1.49M +$275K +859 +21%
LCM
23
Lynx1 Capital Management
Puerto Rico
$1.45M +$1.53M +4,791 New
SPC
24
Sigma Planning Corp
Michigan
$1.36M -$21.1K -66 -1%
Renaissance Technologies
25
Renaissance Technologies
New York
$1.31M +$187K +583 +16%
1
2 3 4

PVLA Hedge Fund Activity: Q4 2021 in Review

81 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2021, worth a combined $136M — down 18% from $165M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PVLA positions and 14 closed out — a net gain of 7 holders — while 20 added to existing stakes and 22 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $9.86M. The largest seller was Invesco, exiting entirely with an estimated $7.76M sold.

  • 81 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2021, up from 75 in Q3 2021.
  • Funds reported $136M of Palvella Therapeutics stock for Q4 2021, down 18% quarter-over-quarter.
  • 21 funds opened new Palvella Therapeutics positions in Q4 2021 and 14 closed out, a net change of +7 holders.
  • The largest Palvella Therapeutics buyer in Q4 2021 was Woodline Partners, an estimated $9.86M added.
  • The largest Palvella Therapeutics seller in Q4 2021 was Invesco, an estimated $7.76M sold.

Based on aggregated 13F filings for Q4 2021.